CytoGenix and USAMRIID to Collaborate in Developing Biodefense synDNA(TM) Vaccines.

HOUSTON -- CytoGenix, Inc. (CYGX.OB) announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

Scientists from CytoGenix and USAMRIID, led by Dr. Connie Schmaljohn, intend to develop and test synDNA[TM] vaccines for the prevention of disease caused by the Ebola virus and several strains of equine encephalitis viruses.

Dr. Malcolm Skolnick, CytoGenix Chief Executive Officer, stated, "We are pleased to have the opportunity to work with Dr. Schmaljohn and the USAMRIID team at Fort Detrick. These disease targets are listed as Category A & B bioterrorism agents/diseases by the Centers for Disease Control. Data collected under this CRADA will help to demonstrate the validity of use of synDNA[TM] vaccines in rapid response platforms including the protection of our nation's military personnel, health providers and other first responders, as well as the general population against a spectrum of existing and emerging terroristic and other infectious diseases."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside the cell. CytoGenix currently holds 11 granted patents and about 36 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute's mission is to conduct basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.